Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance.
about
Nanomaterials for reversion of multidrug resistance in cancer: a new hope for an old idea?Potential for layered double hydroxides-based, innovative drug delivery systemsMiR-375 and Doxorubicin Co-delivered by Liposomes for Combination Therapy of Hepatocellular Carcinoma.Surface De-PEGylation Controls Nanoparticle-Mediated siRNA Delivery In Vitro and In Vivo.Hybrid lipid-polymer nanoparticles for sustained siRNA delivery and gene silencing.Multifunctional nanocarriers for simultaneous encapsulation of hydrophobic and hydrophilic drugs in cancer treatment.Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances.Intelligent Nanoparticles for Advanced Drug Delivery in Cancer TreatmentSynthesis of polysaccharide-block-polypeptide copolymer for potential co-delivery of drug and plasmid DNA.Long-circulating siRNA nanoparticles for validating Prohibitin1-targeted non-small cell lung cancer treatment.Biodegradable cationic polymeric nanocapsules for overcoming multidrug resistance and enabling drug-gene co-delivery to cancer cells.Codelivery of SH-aspirin and curcumin by mPEG-PLGA nanoparticles enhanced antitumor activity by inducing mitochondrial apoptosis.Triple-Layered pH-Responsive Micelleplexes Loaded with siRNA and Cisplatin Prodrug for NF-Kappa B Targeted Treatment of Metastatic Breast Cancer.Anti-tumor Efficiency of Lipid-coated Cisplatin Nanoparticles Co-loaded with MicroRNA-375Multi-functionalized carbon dots as theranostic nanoagent for gene delivery in lung cancer therapyNovel polymer micelle mediated co-delivery of doxorubicin and P-glycoprotein siRNA for reversal of multidrug resistance and synergistic tumor therapy.Codelivery of small molecule hedgehog inhibitor and miRNA for treating pancreatic cancerCore-shell nanocarriers with high paclitaxel loading for passive and active targeting.Green Tea Catechin-Based Complex Micelles Combined with Doxorubicin to Overcome Cardiotoxicity and Multidrug Resistance.Sequential delivery of therapeutic agents using a rationally designed disulfide-linked glycolipid-like nanocarrier.Drug and gene co-delivery systems for cancer treatment.Inhibition of cell proliferation through an ATP-responsive co-delivery system of doxorubicin and Bcl-2 siRNA.Bioinspired Nano-Prodrug with Enhanced Tumor Targeting and Increased Therapeutic Efficiency.Nanoparticle-mediated co-delivery of chemotherapeutic agent and siRNA for combination cancer therapy.Programmed co-delivery of paclitaxel and doxorubicin boosted by camouflaging with erythrocyte membrane.Codelivery of anticancer drugs and siRNA by mesoporous silica nanoparticles.Tackling breast cancer chemoresistance with nano-formulated siRNA.Self-immolative polycations as gene delivery vectors and prodrugs targeting polyamine metabolism in cancer.Carbohydrate-based amphiphilic nano delivery systems for cancer therapy.ZEB1 knockdown mediated using polypeptide cationic micelles inhibits metastasis and effects sensitization to a chemotherapeutic drug for cancer therapy.Recent applications of the combination of mesoporous silica nanoparticles with nucleic acids: development of bioresponsive devices, carriers and sensors.Reversal of lung cancer multidrug resistance by pH-responsive micelleplexes mediating co-delivery of siRNA and paclitaxel.Polymers in the Co-delivery of siRNA and Anticancer Drugs for the Treatment of Drug-resistant Cancers.Multifunctional Nanomaterials and Their Applications in Drug Delivery and Cancer Therapy.Combinatorial therapeutic approaches with RNAi and anticancer drugs using nanodrug delivery systems.Nanomaterial-Enabled Cancer Therapy.Nanoformulations for combination or cascade anticancer therapy.Natural and artificial small RNAs: a promising avenue of nucleic acid therapeutics for cancer.Peptide-tunable drug cytotoxicity via one-step assembled polymer nanoparticles.Multifunctional magnetic co-delivery system coated with polymer mPEG-PLL-FA for nasopharyngeal cancer targeted therapy and MR imaging.
P2860
Q27500424-124A2C54-C977-4E1E-93A2-AA1DE7ABFE3FQ30391504-0B372060-8D62-4368-B015-587890C89E53Q33635350-84AA51DB-03BC-4D9B-B794-CB3EA97FDD79Q33821050-DC0ACB6E-93B4-494B-8E52-8A203D9371DBQ33831440-9323EE4D-857C-412E-84C8-845E2E281D59Q34440323-AB9C2132-F31F-49DE-855C-9197BDB2C7A1Q34622662-0517421C-5994-4208-BA87-5D8A09FC5A53Q35000572-8691171A-6EBB-4188-A2E1-008354AD873EQ35575232-C179BF8C-340E-4FD5-9F18-DD5E6ADB945CQ35796255-8E97EDF3-831A-4AEC-92B7-638855B19F7DQ35908348-23345047-0301-457F-89A1-53178F818EE8Q35991005-E9140EDC-2900-4001-9625-FD5F82AF8E1FQ36372323-30F86000-8436-4C4E-820F-74BB8A99183CQ36372357-53AE04A3-DA75-471D-A69A-AA126371F6CDQ36583404-FBD1905E-DA29-4D9B-A7D9-B8D029B06027Q36748360-879B07AD-4A2C-45CC-9A80-DCD2FF7E14E8Q36791689-37502A55-FE11-4CE2-9E58-70364E138A18Q36986079-E864A397-DFC2-454F-A3B8-87DAE2ECFD3EQ37045928-9D0F62A0-DABE-4F7D-BEBB-789A17E5A5D8Q37696302-0E6F5FD0-5F4C-4854-89B2-1475C48B3673Q38556764-C281C10D-2FDD-4561-B4ED-0A0C36FE5949Q38696439-BBAC9290-D793-466A-A901-3485F6430E0DQ38842836-368203A2-E9F3-4B6A-A66A-9AEC33355B18Q38874499-C9139BAF-3105-40A8-8E74-0582709CC80DQ38912804-6D9C3362-3B81-4DBF-8A49-45F503517DD2Q38943053-E0641A1A-4176-49AD-8E5D-70C4EEDD371DQ38959517-DC00F8D4-07CE-4C06-9CCE-200C081EF219Q38963161-353A79E4-DC90-4678-B556-8E2EB1423F6AQ38974572-490F69E5-1144-41BA-988F-DEAE9C7DAD09Q38974682-BD5E69AE-0E5E-49B6-8F8D-771E2CAD48B7Q39096024-4716D9D5-4353-4C1B-B7EA-15304665D49AQ39106943-73169104-A1F6-4F96-8D3B-D054F9A65F49Q39125540-CBF89E86-0C6D-4A4C-943C-5285434B2791Q39202694-20C085E0-D7FA-4127-AD64-43DB86594C41Q39317565-EFECE779-59DA-46B1-8D70-484761C06B55Q39323096-CB5431EF-1E55-4829-B303-3DFD44C66AE7Q39380111-2C9115DF-397F-48D2-9E03-D5432D794027Q41514193-49047556-7593-483E-B306-7F5C1D95E4B9Q44408453-E812AC1C-C9A3-4997-A74A-C32EE8D43F66Q45864647-59CC2FB7-D313-4546-ABAE-526895781134
P2860
Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Co-delivery of siRNA and thera ...... to overcome cancer resistance.
@ast
Co-delivery of siRNA and thera ...... to overcome cancer resistance.
@en
type
label
Co-delivery of siRNA and thera ...... to overcome cancer resistance.
@ast
Co-delivery of siRNA and thera ...... to overcome cancer resistance.
@en
prefLabel
Co-delivery of siRNA and thera ...... to overcome cancer resistance.
@ast
Co-delivery of siRNA and thera ...... to overcome cancer resistance.
@en
P2860
P1433
P1476
Co-delivery of siRNA and thera ...... to overcome cancer resistance.
@en
P2093
Mar Creixell
Nicholas A Peppas
P2860
P304
P356
10.1016/J.NANTOD.2012.06.013
P577
2012-08-01T00:00:00Z